March 2, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Most on Briumvi show no MS activity after 6 months More than half of the people with relapsing forms of multiple sclerosis (MS) who received Briumvi (ublituximab) in the ULTIMATE clinical trials had no signs of disease activity over the first six months of the trial —…
March 1, 2023 News by Marisa Wexler, MS ACTRIMS 2023: HIV-positive people found to be less likely to develop MS People infected with the human immunodeficiency virus (HIV) — including HIV-positive individuals who received antiretroviral treatment at some point after infection — are significantly less likely to develop multiple sclerosis (MS), a…
March 1, 2023 News by Marisa Wexler, MS ACTRIMS 2023: MS clinical research lacks diversity, representation Nonwhite populations are underrepresented in research that tests therapies for multiple sclerosis (MS), meaning most available data on a treatment’s effectiveness and safety can’t be generalized to all patients. “The absence of diversity in MS research is a…
March 1, 2023 News by Marisa Wexler, MS ACTRIMS 2023: CNM-Au8 bound for Phase 3 testing after positive data Treatment with the experimental oral suspension therapy CNM-Au8 led to improvements in measures of vision, cognitive and motor function, and brain health for people with multiple sclerosis (MS), according to data from the proof-of-concept VISIONARY-MS trial. Bolstered…
February 28, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Astrocyte receptors may help to ease MS cognitive issues Activating certain receptors on astrocytes — a type of nerve support cell — may offer a way of treating cognitive problems in multiple sclerosis (MS), according to recent research. MS mouse models genetically engineered to lack these receptors,…
February 28, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Intermittent fasting shows potential to lessen MS severity Limiting calorie intake over two days of each week for three months led to beneficial immune and metabolic changes, as well as improvements in cognitive function, among people with relapsing-remitting multiple sclerosis (RRMS), a study found. A restrictive…
February 27, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Loss of myelin in spinal cord tied to MS disability A greater loss of myelin — the protective coating around nerve fibers — in the part of the spinal cord found in the neck was associated with worse disability in people with multiple sclerosis, data from a…
February 27, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Should EBV be targeted in MS? Experts debate. A history of infection with Epstein-Barr virus (EBV) has been shown to be a strong risk factor for developing multiple sclerosis (MS) — but is targeting the virus a viable strategy for MS prevention or treatment? This…
February 27, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: ‘Bacteria X’ in gut microbiome may drive inflammation A certain bacterial species is enriched in the gut of people with secondary progressive multiple sclerosis (SPMS) and may promote neuroinflammation and drive disability progression in these patients, a study found. When isolated from SPMS patients and given…
February 24, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Anxiety, depression more common in MS before onset Psychiatric symptoms such as depression and anxiety are more common among multiple sclerosis (MS) patients in the five years leading up to disease onset than in people from the general population, according to a recent analysis. Individuals who…